Significance of ultrasonography combined with shear wave elastography in the diagnosis of prostate cancer

In order to explore the diagnostic value of ultrasound combined with shear wave elastography (SWE) for prostate cancer (PCa), 120 patients with suspected prostate cancer were selected for SWE, contrast-enhanced ultrasound (CEUS), SWE and CEUS combined examination. The results showed that among the 120 patients, 57 cases were diagnosed as prostate cancer and 63 cases as benign prostatic lesions by biopsy. Among 58 cases of PCa diagnosed by SWE, 46 cases were confirmed by pathology, with a sensitivity of 80.70% and a specificity of 77.20%. Among 54 cases of PCa diagnosed by CEUS, 41 cases were confirmed by pathology, with a sensitivity of 80.70% and a specificity of 77.20%. 61 patients with PCa were diagnosed by we and CEUS, and 51 patients were diagnosed by pathology. The sensitivity, specificity and accuracy were 89.47%, 84.70% and 85.38%, respectively. Receiver operating characteristic (ROC) curve results showed that the area under the curve (AUC) of swe and CEUS was 0.944, showing the highest diagnostic efficacy. It can be seen that the combined use of SWE and CEUS provides a more superior diagnostic effect for PCa.

Prostate cancer; Shear wave elastography; Ultrasonography; Diagnostic value

[1] Liu L, Sun FZ, Zhang PY, Xiao Y, Yue X, Wang DM, et al. Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature. Aging Male. 2023; 26: 2252102.

[2] Surintrspanont J, Zhou M. Prostate pathology: what is new in the 2022 WHO classification of urinary and male genital tumors? Pathologica. 2023; 115: 41–56.

[3] Low JY, Ko M, Hanaratty B, Patel RA, Bhamidipati A, Heaphy CM, et al. Genomic characterization of prostatic basal cell carcinoma. American Journal of Pathology. 2023; 193: 4–10.

[4] Netto GJ, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, et al. The 2022 world health organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors. European Urology. 2022; 82: 469–482.

[5] Pokhrel A, Heravi O, Enayati L, Nelson R, Mooppan U, Wu RC, et al. Association between prostate carcinoma and multiple myeloma. Discovery Medicine. 2023; 35: 664–672.

[6] Zhu S, Zhao JG, Nie L, Yin WL, Zhang YW, Zhao FN, et al. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P). BMC Medicine. 2022; 20: 237.

[7] Han M, Li FI, Zhang YH, Dai PF, He J, Li YG, et al. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer. Cancer Cell. 2022; 40: 1306–1323.e8.

[8] Chen CC, Tran W, Song K, Sugimoto T, Obusan MB, Wang L, et al. Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. Cancer Cell. 2023; 41: 2066–2082.e9.

[9] Lin XQ, Shi QY, Yang XJ. Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma. Human Pathology. 2022; 130: 36–46.

[10] Tariq A, Reed AEM, Morton A, Porten S, Vela I, Williams ED, et al. Urothelial carcinoma and prostate-specific membrane antigen: cellular, imaging, and prognostic implications. European Urology Focus. 2022; 8: 1256–1269.

[11] Jia L, Bin H, Bing H, Jin H. CEUS examination of the outcome of radiofrequency ablation of canine prostate lesions. Minimally Invasive Therapy & Allied Technologies. 2021; 30: 334–340.

[12] Kunikowska J, Cieslak B, Gierej B, Patkowski W, Kraj L, Kotulski M, et al. [68 Ga]Ga-prostate-specific membrane antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 883–892.

[13] Licen U, Kozinc Z. Using shear-wave elastography to assess exercise-induced muscle damage: a review. Sensors. 2022; 22: 7574.

[14] Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, et al. The 2019 genitourinary pathology society (GUPS) white paper on contemporary grading of prostate cancer. Archives of Pathology & Laboratory Medicine. 2021; 145: 461–493.

[15] Tyloch DJ, Tyloch JF, Adamowicz J, Neska-Dlugosz I, Grzanka D, Van Breda S, et al. Comparison of strain and shear wave elastography in prostate cancer detection. Ultrasound in Medicine and Biology. 2023; 49: 889–900.

[16] Gupta R, Mahajan M, Sharma P. Correlation between prostate imaging reporting and data system version 2, prostate-specific antigen levels, and local staging in biopsy-proven carcinoma prostate: a retrospective study. International Journal of Applied and Basic Medical Research. 2021; 11: 32–35.

[17] Pham THN, Schulze-Hagen MF, Rahnama’i MS. Targeted multiparametric magnetic resonance imaging/transrectal ultrasound-guided (mpMRI/TRUS) fusion prostate biopsy versus systematic random prostate biopsy: a comparative real-life study. Cancer Reports. 2024; 7: e1962.

[18] Zong Y, Montironi R, Massari F, Jiang Z, Lopez-Beltran A, Wheeler TM, et al. Intraductal carcinoma of the prostate: pathogenesis and molecular perspectives. European Urology Focus. 2021; 7: 955–963.

[19] de Kouchkovsky I, Chan EMY, Schloss C, Poehlein C, Aggarwal R. Diagnosis and management of neuroendocrine prostate cancer. Prostate. 2024; 84: 426–440.

[20] Kalampokis N, Grivas N, Karavitakis M, Leotsakos I, Katafigiotis I, Moschovas MC, et al. Nondetectable prostate carcinoma (pT0) after radical prostatectomy: a narrative review. Current Oncology. 2022; 29: 1309–1315.

[21] Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. European Urology Oncology. 2021; 4: 877–892.

[22] Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors—a systematic review. European Urology. 2023; 84: 191–206.

[23] Dorfinger J, Ponholzer A, Stolzlechner M, Lenart S, Baltzer P, Toepker M. MRI/ultrasound fusion biopsy of the prostate compared to systematic prostate biopsy—effectiveness and accuracy of a combined approach in daily clinical practice. European Journal of Radiology. 2022; 154: 110432.

[24] Dias AB, O’Brien C, Correas JM, Ghai S. Multiparametric ultrasound and micro-ultrasound in prostate cancer: a comprehensive review. British Journal of Radiology. 2022; 95: 20210633.

[25] Gurwin A, Kowalczyk K, Knecht-Gurwin K, Stelmach P, Nowak L, Krajewski W, et al. Alternatives for MRI in prostate cancer diagnostics—review of current ultrasound-based techniques. Cancers. 2022; 14: 1859.

[26] Keskin ET, Kaplanoglu V, Senocak C, Basar H, Bozkurt OF. Transrectal shear wave elastography for detection of prostate cancer. Urologia Journal. 2023; 90: 230–235.

[27] Secasan CC, Onchis D, Bardan R, Cumpanas A, Novacescu D, Botoca C, et al. Artificial intelligence system for predicting prostate cancer lesions from shear wave elastography measurements. Current Oncology. 2022; 29: 4212–4223.

[28] Morris DC, Chan DY, Palmeri ML, Polascik TJ, Foo WC, Nightingale KR. Prostate cancer detection using 3-D shear wave elasticity imaging. Ultrasound in Medicine and Biology. 2021; 47: 1670–1680.

[29] Anbarasan T, Wei C, Bamber JC, Barr RG, Nabi G. Characterisation of prostate lesions using transrectal shear wave elastography (SWE) ultrasound imaging: a systematic review. Cancers. 2021; 13: 122.